Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDTX NASDAQ:CYTK NASDAQ:MTSR NASDAQ:PCVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDTXCidara Therapeutics$62.90-0.6%$41.88$10.14▼$66.94$1.28B1.18646,574 shs302,038 shsCYTKCytokinetics$36.69-2.5%$34.41$29.31▼$59.39$4.50B0.641.28 million shs1.09 million shsMTSRMetsera$34.89+5.8%$32.59$12.30▼$47.40$3.47BN/A1.03 million shs2.06 million shsPCVXVaxcyte$33.02-2.7%$34.44$27.66▼$121.06$4.38B1.211.17 million shs1.11 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDTXCidara Therapeutics-0.65%+1.70%+31.40%+190.00%+383.85%CYTKCytokinetics-2.52%-1.32%+6.78%-1.77%-37.82%MTSRMetsera+5.76%-13.79%+20.89%+36.02%+3,488,999,900.00%PCVXVaxcyte-2.74%-9.86%-0.75%-6.70%-58.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDTXCidara Therapeutics2.8836 of 5 stars2.62.00.04.60.61.70.0CYTKCytokinetics4.0154 of 5 stars4.41.00.04.62.60.80.0MTSRMetseraN/AN/AN/AN/AN/AN/AN/AN/APCVXVaxcyte2.2389 of 5 stars3.62.00.00.03.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDTXCidara Therapeutics 3.11Buy$57.29-8.93% DownsideCYTKCytokinetics 2.88Moderate Buy$70.9293.30% UpsideMTSRMetsera 3.00Buy$55.0057.64% UpsidePCVXVaxcyte 3.10Buy$136.50313.39% UpsideCurrent Analyst Ratings BreakdownLatest CDTX, PCVX, MTSR, and CYTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025CYTKCytokineticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform7/9/2025CDTXCidara TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$69.006/30/2025CDTXCidara TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$59.006/24/2025CDTXCidara TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/24/2025CDTXCidara TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$35.00 ➝ $75.006/24/2025CDTXCidara TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$50.00 ➝ $68.006/23/2025CDTXCidara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$41.00 ➝ $53.006/23/2025CDTXCidara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$36.00 ➝ $54.006/23/2025CDTXCidara TherapeuticsWBB SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy$45.006/20/2025MTSRMetseraWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$65.006/18/2025CDTXCidara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$41.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDTXCidara Therapeutics$1.27M998.48N/AN/A$14.92 per share4.22CYTKCytokinetics$18.47M237.24N/AN/A($1.15) per share-31.90MTSRMetseraN/AN/AN/AN/A$4.28 per shareN/APCVXVaxcyteN/AN/AN/AN/A$26.52 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDTXCidara Therapeutics-$169.83M-$29.47N/AN/AN/AN/A-73.04%-54.28%8/7/2025 (Estimated)CYTKCytokinetics-$589.53M-$5.29N/AN/AN/A-3,201.47%N/A-43.75%8/7/2025 (Estimated)MTSRMetsera-$209.13MN/A0.00∞N/AN/AN/AN/AN/APCVXVaxcyte-$463.93M-$3.99N/AN/AN/AN/A-17.12%-16.26%8/5/2025 (Estimated)Latest CDTX, PCVX, MTSR, and CYTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CDTXCidara Therapeutics-$1.87N/AN/AN/AN/AN/A8/7/2025Q2 2025CYTKCytokinetics-$1.32N/AN/AN/A$1.95 millionN/A8/5/2025Q2 2025PCVXVaxcyte-$1.12N/AN/AN/AN/AN/A7/28/2025Q2 2025MTSRMetseraN/A-$0.66N/A-$0.66N/AN/A5/14/2025Q1 2025PCVXVaxcyte-$1.02-$1.04-$0.02-$1.04N/AN/A5/12/2025Q1 2025MTSRMetseraN/A-$1.03N/A-$1.03N/AN/A5/8/2025Q1 2025CDTXCidara Therapeutics-$5.45-$1.66+$3.79-$1.66N/AN/A5/6/2025Q1 2025CYTKCytokinetics-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDTXCidara TherapeuticsN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDTXCidara TherapeuticsN/A3.873.87CYTKCytokineticsN/A5.995.99MTSRMetseraN/A5.266.55PCVXVaxcyteN/A17.7017.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDTXCidara Therapeutics35.82%CYTKCytokineticsN/AMTSRMetseraN/APCVXVaxcyte96.78%Insider OwnershipCompanyInsider OwnershipCDTXCidara Therapeutics3.89%CYTKCytokinetics2.70%MTSRMetseraN/APCVXVaxcyte3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDTXCidara Therapeutics9020.16 million19.38 millionNo DataCYTKCytokinetics250119.43 million116.20 millionOptionableMTSRMetsera81105.06 millionN/AN/APCVXVaxcyte160129.00 million125.01 millionOptionableCDTX, PCVX, MTSR, and CYTK HeadlinesRecent News About These CompaniesVaxcyte, Inc. (PCVX)’s VAX-24 Achieves Phase 2 Success in InfantsJuly 31 at 11:49 AM | finance.yahoo.comVaxcyte, Inc. (PCVX)’s VAX-24 Achieves Phase 2 Success in InfantsJuly 31 at 11:49 AM | insidermonkey.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by TD Asset Management IncJuly 31 at 5:01 AM | marketbeat.comFiera Capital Corp Invests $13.56 Million in Vaxcyte, Inc. (NASDAQ:PCVX)July 30 at 4:11 AM | marketbeat.comSkandinaviska Enskilda Banken AB publ Acquires New Position in Vaxcyte, Inc. (NASDAQ:PCVX)July 30 at 4:11 AM | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Receives $136.50 Average PT from AnalystsJuly 30 at 3:11 AM | americanbankingnews.comVaxcyte (PCVX) Projected to Post Earnings on TuesdayJuly 29, 2025 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Stake Lifted by Envestnet Asset Management Inc.July 27, 2025 | marketbeat.comTeachers Retirement System of The State of Kentucky Acquires 6,929 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)July 26, 2025 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Recommendation of "Buy" from AnalystsJuly 25, 2025 | marketbeat.comVictory Capital Management Inc. Has $8.34 Million Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)July 25, 2025 | marketbeat.comNew York State Common Retirement Fund Increases Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)July 22, 2025 | marketbeat.comJennison Associates LLC Has $42.51 Million Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)July 20, 2025 | marketbeat.comC WorldWide Group Holding A S Makes New $3.59 Million Investment in Vaxcyte, Inc. (NASDAQ:PCVX)July 18, 2025 | marketbeat.comMizuho Maintains an Overweight Rating on Vaxcyte (PCVX)July 16, 2025 | insidermonkey.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by TimesSquare Capital Management LLCJuly 15, 2025 | marketbeat.comPrincipal Financial Group Inc. Has $17.73 Million Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)July 11, 2025 | marketbeat.comBrown Advisory Inc. Acquires 14,049 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)July 10, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Lowers Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)July 4, 2025 | marketbeat.comCantor Fitzgerald Maintains Overweight on Vaxcyte Amid Vaccine Development and ACIP MeetingJuly 2, 2025 | msn.com86,244 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Acquired by Peregrine Capital Management LLCJuly 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDTX, PCVX, MTSR, and CYTK Company DescriptionsCidara Therapeutics NASDAQ:CDTX$62.90 -0.41 (-0.65%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$60.00 -2.90 (-4.61%) As of 08/1/2025 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.Cytokinetics NASDAQ:CYTK$36.69 -0.95 (-2.52%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$36.92 +0.23 (+0.64%) As of 08/1/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Metsera NASDAQ:MTSR$34.89 +1.90 (+5.76%) As of 08/1/2025 04:00 PM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.Vaxcyte NASDAQ:PCVX$33.02 -0.93 (-2.74%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$32.91 -0.11 (-0.33%) As of 08/1/2025 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
